Q&A 12 February 2004
Question: I have recently received bonus shares from a company in which I held an investment. The shareholder release indicated that the distribution is tax-free. If I sell the shares, what is the cost base for capital gains tax (CGT) purposes?
Answer:There are two ways bonus shares are issued.
Firstly, they can be issued as a taxable distribution (similar to a dividend reinvestment), in which case the cost base will be determined as the amount of the taxable distribution.
Secondly, they can be issued as a tax-free distribution. In this case, the cost base of the shares is determined by the original holding.
Where the original shareholding was pre-CGT (that is, acquired prior to September 20, 1985), the bonus shares will also be exempt from CGT. Where the original shareholding was post-CGT, the shares will be deemed to be acquired at the date the original shares were acquired and the original cost base will be allocated on a pro rata basis between the bonus shares and the original shareholding.
Example (post-CGT)
Date of Acquisition No. Shares Cost Base
June 10, 2000 10,000 $11,000
If a one for 10 bonus issue was made, the cost base would be pro rata as follows:
Date of Acquisition No. Shares Cost Base
June 10, 2000 10,000 $10,000
June 10, 2000 1,000 $1,000
Jason Menzies is senior technical manager,Integratec .
Got a question? E-mail:
Recommended for you
Compared to four years ago when the divide between boutique and large licensees were largely equal, adviser movements have seen this trend shift in light of new licensees commencing.
As ongoing market uncertainty sees advisers look beyond traditional equity exposure, Fidante has found adviser interest in small caps and emerging markets for portfolio returns has almost doubled since April.
CoreData has shared the top areas of demand for cryptocurrency advice but finds investors are seeking advisers who actively invest in the asset themselves.
With regulators ‘raising the bar’ on retirement planning, Lonsec Research and Ratings has urged advisers to place greater focus on sequencing and longevity risk as they navigate clients through the shifting landscape.
